Search

Your search keyword '"Goodspeed, Wendy"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Goodspeed, Wendy" Remove constraint Author: "Goodspeed, Wendy"
28 results on '"Goodspeed, Wendy"'

Search Results

1. Venous and arterial thrombosis in patients with VEXAS syndrome

2. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis

3. Opportunistic Infections, Mortality Risk, and Prevention Strategies in Patients With Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome.

5. Thrombotic Manifestations in Patients with Vexas Syndrome

6. A prospective observational cohort study and systematic review of 40 patients with mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome

9. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS

13. Phase II Trial of Pirfenidone in Children and Young Adults With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

14. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease

15. Discordance in patient and physician global assessment in relapsing polychondritis.

20. 243. CLINICAL FEATURES AND PULMONARY FUNCTION TEST FINDINGS ASSOCIATED WITH LARGE AIRWAY DISEASE IN RELAPSING POLYCHONDRITIS

21. Phase I trial and pharmacokinetic (PK) study of satraplatin in children and young adults with refractory solid tumors including brain tumors.

22. A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors

23. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group

24. Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group

25. Abstract A5: Phase I trial and pharmacokinetic study of cediranib in children with recurrent or refractory solid tumors

27. A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors

28. A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

Catalog

Books, media, physical & digital resources